DEEXA-C eye/ear drops

DEEXA-C eye/ear drops

DEEXA-C eye/ear drops

DEEXA-C is a clear colorless solution which is a combination of corticosteroids and antibiotics.

Dexamethasone: Very potent and highly selective glucocorticoid. Long acting. Cause marked, pituitary adrenal suppression, but fluid retention and hypertension are not a problem. It meets any emergency with intensified potency and strikingly rapid corticosteroid action, thus ensuring speedy reversal of the situation in the patients favour.

Chloramphenicol: chloramphenicol, a broad-spectrum antibiotic, thus combination yields excellent results in inflammation of the anterior uvea (iritis, iridocylitis)

DEEXA-C eye/ear drops


Dexamethasone: when given topically to the eye, dexamethasone is absorbed into the aqueous humor, cornea, iris, choroid, ciliary body and retina. Systemic absorption occurs but may be significant only at higher dosages or in extended paediatric therapy. A volume of distribution has been quoted as 0.58 l/kg. Over 60% of circulating steroids are excreted in the urine within 24 hours, largely as unconjugated steroid. Dexamethasone sodium phosphate is rapidly converted to dexamethasone within the circulation. Up to 77% of dexamethasone is bound to plasma from proteins, the mean plasma half-life is 3.6+/- 0.9h. Dexamethasone also appears to be cleared more rapidly from the circulation of the fetus and neonate than in the mother.

Chloramphenicol: chloramphenicol is an extremely well established antibiotic and the successful use of the eye drops is well documented. Chloramphenicol is found in measurable amounts in the aqueous humor following local application to the eye


Dexamethasone/chloramphenicol drops are used to treat a variety of eye infections. Conditions treated include cornea infections, allergies, scleritis, episcleritis, conjunctivitis, uveal tract infections and sclera. The eye drop solution contains antibiotic and steroidal benefits which work to reduce inflammation and impair bacterial from reproducing.


Hypersensitivity to dexamethasone/chloramphenicol or to any other ingredient of the drops. Possible symptoms include difficulty breathing, difficulty swallowing, swelling, chest tightness, skin rashes and hives.

Dosage and directions for use

Dosage and usage often depends on the severity of the condition as well as the patient’s medical history and current health condition.

Tighten the cap on the nozzle. Use this solution within one month after opening the container. The spike in the cap will pierce the tip of the bottle. Replace the cap after every use.

Dexamethasone sodium phosphate & chloramphenicol eye/ear drops. One or two drops is instilled into the affected eyes every three or four hours or more frequently if deemed advisable by the prescribing physician. Administration should be continued day and night for the first 48 hours, after which the interval between applications may be increased. Treatment should be continued for at least 48 hours after the eye appears normal.

Before applying, wash your hands well and shake the bottle several times to mix the sys drop solution. Administration is quite simple, first tilt your head back and hold your bottom eyelid open using your spare hand. Then, hold the eye dropper over the eye and carefully squeeze the prescribed number of drops into the eye. Immediately close the eyelid and keep it closed for at least 1 minute. While the eyelid is closed, apply gentle pressure to the inside corner of the eye to prevent the solution from draining into the tear ducts.

Adverse effects

Adverse effects can occur when using dexamethasone sodium phosphate and chloramphenicol eye drops however most side effects are only mild and not persistent. If any side effects persist, worsen or become worrying, consult your physician as soon as possible. Possible side effects include: eye irritation, eye itchiness, eye dryness, watery eyes, blurry vision, headaches and nausea.

Drug interactions

The risk of increased intraocular pressure associated with prolonged corticosteroid therapy may be more likely to occur with concomitant use of anticholinergic: atropine and related compounds and other phosphate-containing eye medications. Dexamethasone therapeutically efficacy may be reduced by phenytoin, phenobarbitone, ephedrine and rifampicin. Glucocorticoids may increase plasma salicylate clearance, ritonavir and cobicistat may decrease dexamethasone clearance resulting in increased effects. Chloramphenicol may interact with bone marrow suppressant drugs.

Leave a Reply

%d bloggers like this: